
- Get in Touch with Us
Last Updated: Apr 25, 2025 | Study Period: 2024-2030
Methylcobalamin (mecobalamin, MeCbl, or MeB12) is acobalamin, a form ofvitamin B12. It differs fromcyanocobalaminin that thecyano groupat the cobalt is replaced with amethyl group.
Methylcobalamin features an octahedral cobalt(III) centre and can be obtained as bright red crystals. From the perspective ofcoordination chemistry, methylcobalamin is notable as a rare example of a compound that contains metalâalkyl bonds.Nickelâmethyl intermediates have been proposed for the final step ofmethanogenesis.
Methylcobalamin is equivalent physiologically to vitamin B12,and can be used to prevent or treat pathology arising from a lack of vitamin B12intake (vitamin B12deficiency).
Methylcobalamin is also used in the treatment ofperipheral neuropathy,diabetic neuropathy, and as a preliminary treatment foramyotrophic lateral sclerosis.
Methylcobalamin that is ingested is not used directly as a cofactor, but is first converted byMMACHCinto cob(II)alamin.
Cob(II)alamin is then later converted into the other two forms, adenosylcobalamin and methylcobalamin for use as cofactors. That is, methylcobalamin is first dealkylated and then regenerated.
METHYLCOBALAMIN MARKET SIZE AND FORECAST
The Global METHYLCOBALAMIN market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
Pregabalin 75 mg and Methylcobalamin 750 mcg Capsule 10's - Pregabalin 75 mg and Methylcobalamin 750 mcg Capsule 10's belongs to the class of medications âanticonvulsantsâ used in the treatment of neuropathic pain. Neuropathic pain is a chronic (long-term) progressive nerve disease that causes nerve pain due to nerve damage or the nervous system's malfunctioning.
It is mostly seen in patients who had suffered a trauma or nerve injury, diabetes, vitamin deficiencies, cancer, multiple sclerosis (disease of the brain and spinal cord), shingles (a viral infection), and HIV.
Pregabalin 75 mg and Methylcobalamin 750 mcg Capsule 10's is a combination of two medicines: Pregabalin and Methylcobalamin.
Pregabalin acts by decreasing the pain signals sent by a damaged nerve in the body. On the other hand, Methylcobalamin helps rejuvenate and protect damaged nerve cells by producing a substance called myelin (outer protective layer of nerve cell - neuron).
Pregabalin is an anticonvulsant that affects the brain's chemicals that send pain signals across the nervous system. It works by binding to the specific site on voltage-gated calcium channels (responsible for excitatory response), thereby decreasing brain activity.
This effect helps in relieving nerve pain and lowers the risk of seizures. On the other hand, Methylcobalamin is a form of vitamin B12 that helps rejuvenate and protect damaged nerve cells by producing a substance called myelin (outer protective layer of nerve cells).
Together, Pregabalin 75 mg and Methylcobalamin 750 mcg Capsule 10's helps in providing relief from neuropathic pain and improved nerve signal conduction.
Sl no | Topic |
1 | Market Segmentation |
2 | Scope of the report |
3 | Abbreviations |
4 | Research Methodology |
5 | Executive Summary |
6 | Introduction |
7 | Insights from Industry stakeholders |
8 | Cost breakdown of Product by sub-components and average profit margin |
9 | Disruptive innovation in the Industry |
10 | Technology trends in the Industry |
11 | Consumer trends in the industry |
12 | Recent Production Milestones |
13 | Component Manufacturing in US, EU and China |
14 | COVID-19 impact on overall market |
15 | COVID-19 impact on Production of components |
16 | COVID-19 impact on Point of sale |
17 | Market Segmentation, Dynamics and Forecast by Geography, 2024-2030 |
18 | Market Segmentation, Dynamics and Forecast by Product Type, 2024-2030 |
19 | Market Segmentation, Dynamics and Forecast by Application, 2024-2030 |
20 | Market Segmentation, Dynamics and Forecast by End use, 2024-2030 |
21 | Product installation rate by OEM, 2023 |
22 | Incline/Decline in Average B-2-B selling price in past 5 years |
23 | Competition from substitute products |
24 | Gross margin and average profitability of suppliers |
25 | New product development in past 12 months |
26 | M&A in past 12 months |
27 | Growth strategy of leading players |
28 | Market share of vendors, 2023 |
29 | Company Profiles |
30 | Unmet needs and opportunity for new suppliers |
31 | Conclusion |
32 | Appendix |